Wolverine Asset Management’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Wolverine Asset Management’s Portfolio EUCRU Stock Details EUCRU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,635	Closed	-$26.3K	–	2281
2022 Q4	$26.3K	Sell	2,635 -1,275	-33%	-$12.7K	﹤0.01%	1483
2022 Q3	$39K	Sell	3,910 -90	-2%	-$897	﹤0.01%	1664
2022 Q2	$40K	Hold	4,000	–	–	﹤0.01%	1636
2022 Q1	$39K	Buy	+4,000	New	+$39.7K	﹤0.01%	1594
2021 Q2	–	Sell	-1,107	Closed	-$11K	–	2503
2021 Q1	$11K	Sell	1,107 -2,253	-67%	-$24K	﹤0.01%	1860
2020 Q4	$35K	Buy	+3,360	New	+$34.1K	﹤0.01%	1385

Other funds holding EUCRU

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Wolverine Asset Management's EUCRU Position: Q1 2023 in Review

Wolverine Asset Management sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q1 2023, closing a stake of 2,635 shares — an estimated $26.3K sold.

Wolverine Asset Management first reported a position in EUCRU in Q4 2020 and held it in 6 quarters. The position peaked at $40K in Q2 2022. 4 funds tracked by Wall St. Rank hold EUCRU as of Q1 2023.

Wolverine Asset Management reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q1 2023 after selling out during the quarter.
Wolverine Asset Management sold 2,635 Eucrates Biomedical Acquisition Corp. Unit shares in Q1 2023, an estimated $26.3K.
Wolverine Asset Management first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 6 quarters.
Wolverine Asset Management's Eucrates Biomedical Acquisition Corp. Unit position peaked at $40K in Q2 2022.
4 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q1 2023.

Based on Wolverine Asset Management's 13F filing for Q1 2023, filed 8 May 2023.